| 創建日期 | 上市日期 | 董事長 | 總經理 |
|---|---|---|---|
| 101/08/28 | 112/06/12 | 邱壬乙 | 陳翰民 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| -1.4(Q2) | 0 | 5.26 | 0% |
| 實收資本額 | 已發行普通股 | ||
| 759,750,000 | 75,975,000 | ||
| 主要經營業務 | |||
| 新藥開發檢測分析服務及試劑銷售 | |||
| 公司網址 | |||
| energenesis-biomedical.com | |||
華安(6657) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 332 | 341 | -8.5% | -2.6% | 4,113 | 4,173 | -1.4% |
| 2023/07 | 363 | 976 | -31.3% | -62.8% | 3,781 | 3,832 | -1.3% |
| 2023/06 | 528 | 906 | -23.4% | -41.7% | 3,418 | 2,856 | 19.7% |
| 2023/05 | 689 | 434 | 5.5% | 58.8% | 2,890 | 1,950 | 48.2% |
| 2023/04 | 653 | 717 | -19.8% | -8.9% | 2,201 | 1,516 | 45.2% |
| 2023/03 | 814 | 191 | 46.1% | 326.2% | 1,548 | 799 | 93.7% |
| 2023/02 | 557 | 424 | 214.7% | 31.4% | 734 | 608 | 20.7% |
| 2023/01 | 177 | 184 | -82.3% | -3.8% | 177 | 184 | -3.8% |
| 2022/12 | 1,003 | 1,066 | -12.6% | -5.9% | 7,351 | 7,489 | -1.8% |
| 2022/11 | 1,148 | 675 | 234.7% | 70.1% | 6,348 | 6,423 | -1.2% |
| 2022/10 | 343 | 691 | -49.8% | -50.4% | 5,200 | 5,748 | -9.5% |
| 2022/09 | 684 | 452 | 100.6% | 51.3% | 4,857 | 5,057 | -4% |
| 2022/08 | 341 | 865 | -65.1% | -60.6% | 4,173 | 4,605 | -9.4% |
| 2022/07 | 976 | 148 | 7.7% | 559.5% | 3,832 | 3,740 | 2.5% |
| 2022/06 | 906 | 414 | 108.8% | 118.8% | 2,856 | 3,592 | -20.5% |
| 2022/05 | 434 | 729 | -39.5% | -40.5% | 1,950 | 3,178 | -38.6% |
| 2022/04 | 717 | 675 | 275.4% | 6.2% | 1,516 | 2,449 | -38.1% |
| 2022/03 | 191 | 807 | -55% | -76.3% | 799 | 1,774 | -55% |
| 2022/02 | 424 | 335 | 130.4% | 26.6% | 608 | 967 | -37.1% |
| 2022/01 | 184 | 632 | -82.7% | -70.9% | 184 | 632 | -70.9% |
| 2021/12 | 1,066 | 712 | 57.9% | 49.7% | 7,489 | 7,081 | 5.8% |
| 2021/11 | 675 | 867 | -2.3% | -22.1% | 6,423 | 6,369 | 0.8% |
| 2021/10 | 691 | 623 | 52.9% | 10.9% | 5,748 | 5,502 | 4.5% |
| 2021/09 | 452 | 801 | -47.7% | -43.6% | 5,057 | 4,879 | 3.6% |
| 2021/08 | 865 | 561 | 484.5% | 54.2% | 4,605 | 4,078 | 12.9% |
| 2021/07 | 148 | 678 | -64.3% | -78.2% | 3,740 | 3,517 | 6.3% |
| 2021/06 | 414 | 600 | -43.2% | -31% | 3,592 | 2,839 | 26.5% |
| 2021/05 | 729 | 570 | 8% | 27.9% | 3,178 | 2,239 | 41.9% |
| 2021/04 | 675 | 390 | -16.4% | 73.1% | 2,449 | 1,669 | 46.7% |
| 2021/03 | 807 | 455 | 140.9% | 77.4% | 1,774 | 1,279 | 38.7% |
| 2021/02 | 335 | 423 | -47% | -20.8% | 967 | 824 | 17.4% |
| 2021/01 | 632 | 401 | -11.2% | 57.6% | 632 | 401 | 57.6% |
| 2020/12 | 712 | 464 | -17.9% | 53.4% | 7,081 | 6,251 | 13.3% |
| 2020/11 | 867 | 693 | 39.2% | 25.1% | 6,369 | 5,787 | 10.1% |
| 2020/10 | 623 | 608 | -22.2% | 2.5% | 5,502 | 5,094 | 8% |
| 2020/09 | 801 | 612 | 42.8% | 30.9% | 4,879 | 4,486 | 8.8% |
元大S&P500正2(00647L) 歷年營收季增率
無資料可顯示。
評論0